Hudson Bay Capital Management
RGC icon

Hudson Bay Capital Management’s Regencell Bioscience RGC Stock Holding History

Hudson Bay Capital Management’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,107
Closed -$275K – 1562
2025
Q4 		$275K Buy
+13,107
New +$213K ﹤0.01% 932

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Hudson Bay Capital Management's RGC Position: Q1 2026 in Review

Hudson Bay Capital Management sold out of Regencell Bioscience (RGC) in Q1 2026, closing a stake of 13,107 shares — an estimated $275K sold.

Hudson Bay Capital Management first reported a position in RGC in Q4 2025 and held it in 1 quarter. The position peaked at $275K in Q4 2025. 31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

  • Hudson Bay Capital Management reported no remaining Regencell Bioscience position as of Q1 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 13,107 Regencell Bioscience shares in Q1 2026, an estimated $275K.
  • Hudson Bay Capital Management first reported a position in Regencell Bioscience in Q4 2025 and held it in 1 quarter.
  • Hudson Bay Capital Management's Regencell Bioscience position peaked at $275K in Q4 2025.
  • 31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.